Description: Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
Home Page: www.nichiiko.co.jp
1-6-21 Sogawa
Toyama,
930-8583
Japan
Phone:
81 7 6432 2121
Officers
| Name | Title |
|---|---|
| Mr. Yuiichi Tamura | Pres, CEO, Representative Director & Compliance Supervisor |
| Mr. Shuji Ishida | EVP, GM of Admin. Division, Managing Exec. Officer & Director |
| Hiroshi Shimazaki | Sr. Exec. Officer & Head of Quality Assurance & Pharmacovigilance Division |
| Mr. Takashi Kashiwagi | Sr. Exec. Officer & Head of Corp. Strategy & Planning Division |
| Mr. Susumu Kanda | Managing Exec. Officer, GM of the Pres's Office & Director |
| Mr. Hirotoshi Naruse | EVP, Managing Exec. Officer, GM of the Quality Control Division & Director |
| Atsushi Matsumoto | Sr. Exec. Officer |
| Tadashi Kojima | Sr. Exec. Officer |
| Toru Furukawa | Sr. Exec. Officer |
| Keiji Nagae | Sr. Exec. Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 27.5482 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3182 |
| Price-to-Sales TTM: | 0.0004 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 2656 |